Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
522 studies found for:    lupus
Show Display Options
Download search resultsDownload the search results for:
lupus (522 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Terminated
Has Results
Etanercept for the Treatment of Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Drug: Etanercept;   Drug: Lupus Treatment- Standard of Care;   Drug: Placebo
2 Completed Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis
Conditions: SLE;   Lupus Nephritis;   Renal Insufficiency;   End-stage Renal Disease
Interventions: Drug: Tacrolimus;   Drug: cyclophosphamide
3 Recruiting Functional MRI in Lupus Nephritis
Condition: Lupus Nephritis
Intervention:
4 Completed CArdiovascular Risk Assessment STudy in Lupus Erythemathodes (CASTLE)
Condition: Systemic Lupus Erythematosus
Intervention:
5 Terminated Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus
Conditions: Cutaneous Lupus;   Discoid Lupus;   Lupus;   Systemic Lupus Erythematosus
Interventions: Drug: AMG811;   Drug: AMG811 Placebo
6 Completed
Has Results
Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis
Conditions: Lupus Nephritis;   Lupus Erythematosus, Systemic
Interventions: Drug: abatacept;   Drug: cyclophosphamide;   Drug: azathioprine;   Drug: prednisone;   Drug: abatacept placebo;   Drug: azathioprine placebo
7 Completed
Has Results
A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Drug: Rituximab;   Drug: Placebo;   Drug: Mycophenolate mofetil;   Drug: Methylprednisolone;   Drug: Diphenhydramine;   Drug: Acetaminophen;   Drug: Prednisone
8 Terminated Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus
Condition: Subacute Cutaneous Lupus Erythematosus
Interventions: Drug: KRP203 - 1.2mg;   Drug: Placebo to KRP203 - 1.2 mg
9 Completed A Study of the Metabolic Syndrome in Patients With Systemic Lupus Erythematosus
Conditions: Metabolic Syndrome;   Cardiovascular Risk Factors;   Systemic Lupus Erythematosus
Intervention:
10 Completed
Has Results
Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare
Condition: Lupus Nephritis
Interventions: Drug: Mycophenolate sodium;   Drug: Prednisone;   Drug: Methylprednisolone
11 Completed Anti-CD20 in Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Intervention: Drug: Rituximab
12 Completed A Non-drug Study Profiling Cutaneous Lupus
Conditions: Lupus Erythematosus, Cutaneous;   Lupus Erythematosus, Systemic;   Lupus Erythematosus, Discoid
Interventions: Procedure: No intervention, skin biopsy;   Procedure: No intervention, blood collection;   Procedure: No intervention, urine collection
13 Completed Comparing the Therapeutic Efficacy of Pimecrolimus Cream With Betamethasone Cream for Discoid Lupus Erythematosus
Condition: Discoid Lupus Erythematosus
Interventions: Drug: Pimecrolimus 1% cream;   Drug: betamethasone valerate 0.1% cream
14 Completed Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors
Condition: Systemic Lupus Erythematosus
Intervention: Drug: atorvastatin
15 Completed Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients
Condition: Lupus Nephritis
Intervention:
16 Completed Study of Methotrexate in Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Intervention: Drug: Methotrexate and folic acid
17 Completed Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
Conditions: Lupus Erythematosus, Systemic;   Lupus Nephritis
Interventions: Drug: CTLA4-IgG4m (RG2077);   Drug: Cyclophosphamide
18 Terminated The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Drug: mycophenolate sodium;   Drug: cyclophosphamide
19 Terminated A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Patients With Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Intervention: Drug: CEP-33457
20 Completed A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus
Conditions: Lupus Erythematosus, Cutaneous;   Lupus Erythematosus, Systemic
Interventions: Drug: 1 mg/kg CNTO 136;   Drug: 4 mg/kg CNTO 136;   Drug: 10 mg/kg CNTO 136;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years